Dataset Information

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

ABSTRACT: Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.

SUBMITTER: Rasche M

PROVIDER: S-EPMC8151466 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

Rasche Mareike M Zimmermann Martin M Steidel Emma E Alonzo Todd T Aplenc Richard R Bourquin Jean-Pierre JP Boztug Heidrun H Cooper Todd T Gamis Alan S AS Gerbing Robert B RB Janotova Iveta I Klusmann Jan-Henning JH Lehrnbecher Thomas T Mühlegger Nora N Neuhoff Nils V NV Niktoreh Naghmeh N Sramkova Lucie L Stary Jan J Waack Katharina K Walter Christiane C Creutzig Ursula U Dworzak Michael M Kaspers Gertjan G Kolb Edward Anders EA Reinhardt Dirk D

Cancers 20210512 10

Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) ...[more]

PMID: 34066095

Similar Datasets

Project description:BACKGROUND: Children with Down syndrome (DS) are at high risk of infectious toxicity when treated with acute lymphoblastic leukemia chemotherapy protocols optimized in children without DS. Our objective was to determine if children with DS and acute myeloid leukemia (AML) have a different risk of infection when treated with chemotherapy protocols developed for children with DS compared to AML treatment protocols developed for children without DS. METHODS: We conducted a retrospective, population-based cohort study that included DS children???18 years of age with de novo, non-M3 AML diagnosed between January 1995 and December 2004, and treated at 15 Canadian centers. Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle of chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease or death (whichever occurred first). Trained research associates abstracted all information from each site. RESULTS: There were 31 children with DS included; median age was 1.7 (range 0.1-11.1) years. Eleven were treated according to a DS-specific protocol while 20 were treated with non-DS specific protocols. A total of 157 courses of chemotherapy were delivered. Microbiologically documented sterile site infection occurred in 11.9% and 14.3% of DS-specific and non-DS specific AML treatment courses respectively. Sepsis was rare and there were no infection-related deaths. In multiple regression, treatment with a DS-specific protocol was independently associated with a reduction in microbiologically documented sterile site infection (adjusted odds ratio (OR) 0.65, 95% confidence interval (CI) 0.42-0.99; P?=?0.044), and clinically documented infection (adjusted OR 0.36, 95% CI 0.14-0.91; P?=?0.031) but not bacteremia (adjusted OR 0.73, 95% CI 0.44-1.22; P?=?0.231). CONCLUSIONS: Our study suggests that children with DS do not experience excessive infectious toxicity during treatment for AML compared to children without DS. Incorporation of DS-specific AML treatment protocols is associated with a more favorable infection profile for children with DS-AML.

Dataset Information

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

Publications

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets